Greater OS Benefit Among Patients with Advanced Cancer Treated with Matched Targeted Therapy Based on Biomarkers Identified by ctDNA Genotyping By Ogkologos - November 11, 2024 661 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SCRUM-Japan GOZILA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Serplulimab Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma MOST POPULAR ESMO Asia Congress 2024, Singapore, 6-8 December November 27, 2024 Time to take on 9 new Cancer Grand Challenges March 8, 2023 Women Diagnosed with Early Breast Cancer Since 2000 Have About a... October 24, 2024 Clinical Benefit and Safety of Encorafenib Plus Binimetinib in Treatment-Naïve and... June 12, 2023 Load more HOT NEWS New on NCI Websites for July 2019 Combination Chemo Helps People with Leiomyosarcoma Live Longer Cancer Researchers Bring Tools, Experience to COVID-19 Studies Shorter Course of Radiation Is Effective, Safe for Some with Early-Stage...
